1. INTRODUCTION
===============

The human epidermal growth factor receptor 2 ([her]{.smallcaps}2) is a transmembrane tyrosine kinase receptor protein that is part of the [her]{.smallcaps} family of growth factor receptors ([her]{.smallcaps}1 to [her]{.smallcaps}4). The [her]{.smallcaps}2 receptor is involved in cell--cell and cell--stroma communication, primarily through signal transduction involving the Ras/mitogen-activated protein kinase and phosphatidylinositol 3 kinase ([pi]{.smallcaps}3[k]{.smallcaps})/Akt pathways [@b1-co16-4-25]. These signals ultimately promote cell proliferation, survival, and motility. Amplification of the [her]{.smallcaps}2/*neu* gene and resulting overexpression of the [her]{.smallcaps}2 protein occurs in approximately 20% of invasive primary breast cancers [@b2-co16-4-25]. The [her]{.smallcaps}2 alteration in early-stage breast cancer is associated with more aggressive disease and a higher risk of relapse than is seen with [her]{.smallcaps}2-negative cancers [@b3-co16-4-25]--[@b7-co16-4-25].

Trastuzumab is a monoclonal antibody that binds to the extracellular domain of [her]{.smallcaps}2. Several mechanisms of action underlie the antitumour effects of trastuzumab. Trastuzumab blocks [her]{.smallcaps}2-activated cell signalling, thereby reducing cell proliferation and restoring ability to undergo apoptosis by inhibiting the [pi]{.smallcaps}3[k]{.smallcaps}/Akt pathway [@b1-co16-4-25],[@b8-co16-4-25],[@b9-co16-4-25],[a](#fn1-co16-4-25){ref-type="fn"}. The result is increased cellular sensitivity to chemotherapy and radiotherapy [@b10-co16-4-25].

Trastuzumab has been shown to inhibit [her]{.smallcaps}2- regulated angiogenesis [@b8-co16-4-25],[@b11-co16-4-25]--[@b13-co16-4-25] and, in preclinical models, to recruit the immune system through antibody-dependent cellular cytotoxicity, triggering activation of natural killer cell--mediated apoptosis [@b14-co16-4-25]--[@b16-co16-4-25]. Trastuzumab has also been shown to prevent the formation of p95[her]{.smallcaps}2 (a truncated active form of [her]{.smallcaps}2), which may lead to inhibition of tumour development [@b8-co16-4-25],[@b17-co16-4-25].

In pivotal first-line metastatic breast cancer ([mbc]{.smallcaps}) trials ([Table I](#tI-co16-4-25){ref-type="table"}), the addition of trastuzumab to standard systemic chemotherapy treatment resulted in significantly improved time to disease progression, improved response rates, and an overall survival benefit (as compared with chemotherapy alone) [@b18-co16-4-25]--[@b20-co16-4-25]. Consequently, single-agent trastuzumab following chemotherapy or trastuzumab in combination with chemotherapy is now considered standard treatment for [mbc]{.smallcaps} patients who overexpress [her]{.smallcaps}2. In clinical practice, trastuzumab is usually continued until disease progression.

There is considerable controversy regarding the potential clinical benefit of continuing trastuzumab after relapse---that is, therapy beyond disease progression ---as a component of second and subsequent lines of systemic therapy. As well, with the approval and widespread incorporation of trastuzumab as a component of adjuvant systemic therapy for [her]{.smallcaps}2-positive early-stage breast cancers (stages [i]{.smallcaps}--[iii]{.smallcaps}), uncertainty remains regarding the potential role of trastuzumab-based therapy upon relapse.

Data regarding these two clinical questions remain limited and primarily consist of nonrandomized retrospective (Level 3) evidence. The goal of the present paper is to review the current evidence and to outline suggestions from a panel of Canadian oncologists regarding the use of trastuzumab and other [her]{.smallcaps}2-targeted therapies in two key [mbc]{.smallcaps} patient indications:

-   Treatment for women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} progressing on trastuzumab (that is, treatment beyond progression)

-   Treatment for women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} recurring following adjuvant trastuzumab (that is, re-treatment)

2. DEVELOPMENT OF PANEL SUGGESTIONS
===================================

The authors of this paper met in Toronto for a one-day conference in June 2008. The panel reviewed results of the latest trials evaluating trastuzumab and other [her]{.smallcaps}2-targeted agents in the neoadjuvant, adjuvant, and metastatic settings. Based on trial information, suggestions were formulated for each setting. For [mbc]{.smallcaps}, a draft manuscript reviewing the current available data and outlining the suggestions from the panel was initially written by a medical writer (BW) and was reviewed and revised by four main panel members (SD, KP, ShV, and JL). The final manuscript was approved by the remaining seven panel members (JM, SuV, DR, SC, MC, JL, and LP). Published and presented clinical trials results (available as of March 2009) were incorporated into the present document. Support for the initial meeting of the Canadian advisory panel and the development of the present manuscript was provided by an unrestricted educational grant from Hoffmann--La Roche Canada. The authors received an honorarium for attending the meeting, but not for writing the manuscript. The authors are solely responsible for the content of the manuscript, with no restrictions set by the sponsor.

3. TRIALS IN MBC
================

Two major pivotal trials involving more than 650 women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} have examined the role of trastuzumab in combination with systemic chemotherapy as compared with chemotherapy alone in the first-line setting [@b18-co16-4-25]--[@b20-co16-4-25]. In both studies, although different chemotherapeutic regimens were used, the addition of trastuzumab, as compared with chemotherapy alone, significantly prolonged time to disease progression, increased response rate, prolonged duration of response, and increased overall survival benefit ([Table I](#tI-co16-4-25){ref-type="table"}).

Several small, retrospective case--cohort studies have examined the role of continuing trastuzumab beyond progression in second- and subsequent-line therapy with various chemotherapy partners. Overall response rates ranged from 18% to 50% in the second line, 14.3% to 38.1% in the third line, 19.2% to 20% in the fourth line, and less than 10% in fifth-line trastuzumab-based regimens. Time to progression was reported as 4.0--9.0 months in the second line, 3.5--9 months in the third line, 4--4.9 months in the fourth line, and approximately 4 months in fifth-line trastuzumab-based regimens ([Table II](#tII-co16-4-25){ref-type="table"}) [@b21-co16-4-25]--[@b29-co16-4-25].

Similar results of continuing trastuzumab with various chemotherapy partners beyond progression in women with [mbc]{.smallcaps} have been observed in prospective phase [ii]{.smallcaps} trials, although data remain limited. Across studies, overall response rates of 11%--50% were observed after a second-line trastuzumab-based regimen, with a greater than 60% response rate observed with one third-line trastuzumab-based regimen ([Table III](#tIII-co16-4-25){ref-type="table"}). Time to progression ranged from 6 months to 8 months in second-line and 9 months in third-line trastuzumab-based regimens ([Table III](#tIII-co16-4-25){ref-type="table"}) [@b30-co16-4-25]--[@b36-co16-4-25].

The French Hermine trial, a prospective observational study in women who had [her]{.smallcaps}2-positive [mbc]{.smallcaps}, contributed intriguing survival data in the setting of progression [@b37-co16-4-25],[@b38-co16-4-25]. A total of 623 patients were enrolled, of whom 221 (cohort A) received first-line trastuzumab-based therapy (that is, with paclitaxel, docetaxel, vinorelbine, or capecitabine) and 117 (cohort B) received trastuzumab-based therapy as part of second-line treatment [@b38-co16-4-25]. After 2 years of follow-up, significantly longer overall survival was observed in patients treated with first-line trastuzumab (cohort A) as compared with those who discontinued trastuzumab after initial progression ([Table IV](#tIV-co16-4-25){ref-type="table"}). For patients who continued trastuzumab as a component of second-line therapy (cohort B), overall survival from the first trastuzumab treatment was again longer than it was in patients who discontinued trastuzumab ([Table IV](#tIV-co16-4-25){ref-type="table"}). Given the nonrandomized nature of the study and the potential biases involved in the selection of patients who received second-line therapy, the foregoing results must be interpreted with caution. It is feasible that underlying patient characteristics could have contributed to the observed improvement in overall survival in patients who were able to continue to receive trastuzumab therapy at the time of disease progression.

3.1 Randomized Clinical Trials
------------------------------

A recently published study addressed the question of continuing trastuzumab beyond progression after first-line treatment[@b39-co16-4-25] ([Table V](#tV-co16-4-25){ref-type="table"}). This prospective phase [iii]{.smallcaps} trial compared capecitabine plus trastuzumab with capecitabine alone in patients with locally advanced or metastatic breast cancer with disease progression during trastuzumab treatment. Patients could have received up to one prior chemotherapy regimen for [mbc]{.smallcaps}. Patients were required to be trastuzumab-free for fewer than 6 weeks, to have been taking trastuzumab for at least 12 weeks, and to have a baseline left ventricular ejection fraction of 50% or better. A total of 156 (of a planned 482) patients were accrued. During the recruitment phase of the study, lapatinib was registered by the U.S. Food and Drug Administration for the indications being tested, and on the advice of the Independent Data Monitoring Committee, this study was terminated prematurely. The primary objective was time to progression; secondary objectives were safety, objective response rates, clinical benefit rates, and overall survival [@b39-co16-4-25]. Patients received capecitabine (2500 mg/m^2^) for 14 days of a 21-day cycle, and trastuzumab (6 mg/kg) was administered in 3-week cycles. Compared with capecitabine alone, the addition of trastuzumab to capecitabine resulted in significant improvements in time to progression (8.2 months vs. 5.6 months; hazard ratio: 0.69; 95% confidence interval: 0.48 to 0.9; *p* = 0.0338), with significant improvements in overall response rates (48.1% vs. 27.0%, *p* = 0.0115) and clinical benefit rate (75.3% vs. 54.0%, *p* = 0.0068).

Median overall survival was not statistically different (25.5 months vs. 20.4 months, *p* = 0.257). No unexpected toxicities were observed. In the trastuzumab- containing arm, single cases of congestive heart failure, tachyarrhythmia, hypertension, and a drop to below 40% or a 10% decline from baseline in left ventricular ejection fraction were observed.

3.2 Other Targeted Strategies for Treatment Beyond Progression
--------------------------------------------------------------

A number of other agents targeting [her]{.smallcaps}2 and other members of the epidermal growth factor receptor family have been evaluated as single agents or in combination with other chemotherapy partners. These include lapatinib and pertuzumab.

The role of lapatinib, a tyrosine kinase inhibitor that inhibits both [her]{.smallcaps}1 and [her]{.smallcaps}2, was investigated in a prospective randomized phase [iii]{.smallcaps} clinical trial. Women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} who had progressed on trastuzumab (*n* = 324) and who had received anthracyclines and taxanes, were randomized to receive capecitabine alone (2500 mg/m^2^ days 1--14, every 3 weeks) or capecitabine (2000 mg/m^2^ days 1--14, every 3 weeks) with lapatinib (1250 mg/m^2^ twice daily, days 1--14, every 3 weeks) [@b40-co16-4-25],[@b41-co16-4-25]. The primary endpoint was time to progression. Secondary endpoints included progression- free survival, overall survival, clinical benefit, partial response rate, and safety. Women assigned to the combination arm experienced a significantly longer time to progression (27 weeks vs. 19 weeks, *p* = 0.00013) than did those taking capecitabine alone. Overall response rates were higher in the combination arm (24% vs. 14%, *p* = 0.017). The hazard ratio for overall survival in the combination arm (versus capecitabine alone) was 0.78 (95% confidence interval: 0.55 to 1.12; *p* = 0.177; [Table VI](#tVI-co16-4-25){ref-type="table"}). Based on these data, the combination of lapatinib with capecitabine was approved by the U.S. Food and Drug Administration for patients with advanced or metastatic [her]{.smallcaps}2-positive breast cancer who have received prior therapy with an anthracycline, a taxane, and trastuzumab.

Lapatinib was recently approved by Health Canada (May 14, 2009) and is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumours overexpress [her]{.smallcaps}2. Eligible patients should have progressed on taxanes, anthracyclines, and trastuzumab before the start of the lapatinib and capecitabine combination. Health Canada approval was based on improvement in time to progression; no significant improvement in overall survival was observed.

O'Shaughnessy *et al.* examined trastuzumab and lapatinib combinations versus lapatinib alone in women with heavily pretreated [her]{.smallcaps}2-positive [mbc]{.smallcaps} (*n* = 296) progressing on trastuzumab therapy. The primary endpoint was progression-free survival; the secondary endpoints were clinical benefit rate at 24 weeks, response rate, and overall survival. Patients in the intent-to-treat population who received combination therapy experienced a significantly longer median progression-free survival (12.0 weeks vs. 8.4 weeks, *p* = 0.029) and a significantly better clinical benefit rate (25.2% vs. 13.2%, *p* = 0.02). The differences in response rate (10.3% vs. 6.9%, *p* = 0.46) and median overall survival time (51.6 weeks vs. 39.0 weeks, *p* = 0.106) were not statistically significant [@b42-co16-4-25].

Pertuzumab, another humanized monoclonal antibody developed to target a different domain of the [her]{.smallcaps}2 receptor, has been studied in combination with trastuzumab for patients with [her]{.smallcaps}2-positive [mbc]{.smallcaps} and disease progression on, or subsequent to, trastuzumab therapy with two or more prior chemotherapy regimens [@b43-co16-4-25]--[@b46-co16-4-25]. In a phase [ii]{.smallcaps} open-label single-arm study, a clinical benefit rate of 50.0% and an objective response rate of 24.2% (including 16.7% partial response and 7.6% complete response) were observed in 66 evaluable patients [@b46-co16-4-25]. No clinically significant cardiac events were observed.

3.3 MBC After Adjuvant Trastuzumab (Re-treatment)
-------------------------------------------------

There are currently no published clinical trials to guide clinicians in the management of women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} who relapse after receiving adjuvant trastuzumab. A number of actively recruiting phase [ii]{.smallcaps} and [iii]{.smallcaps} studies are addressing this important clinical issue.

The [rhea]{.smallcaps} (Retreatment After Herceptin Adjuvant) study is a nonrandomized phase [ii]{.smallcaps} trial that is examining the efficacy of trastuzumab therapy alone (cohort A) or with docetaxel or paclitaxel (cohort B) in patients who have relapsed 6 months or more after completion of at least 10 months of adjuvant trastuzumab. The choice of cohort will be made for each patient by the investigator, in accordance with the investigator's clinical practice. The planned size for each cohort is 40 patients [@b47-co16-4-25].

Three ongoing phase [iii]{.smallcaps} trials are evaluating first-line systemic therapy regimens for women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} who may or may not have received adjuvant trastuzumab. Although these trials do not specifically address the potential benefit of the addition of trastuzumab to the chemotherapy regimen (versus the absence of trastuzumab), the results of such studies may provide some insight into the role of targeted therapy in this setting.

The [cleopatra]{.smallcaps} trial is examining the efficacy and safety of trastuzumab and docetaxel with or without pertuzumab as first-line chemo-biologic therapy in patients with [her]{.smallcaps}2-positive [mbc]{.smallcaps}, with a disease-free interval of 12 months or more after adjuvant trastuzumab. The primary endpoint is progression-free survival; secondary endpoints are overall survival, response rate, and safety. The targeted sample size is 800 [@b48-co16-4-25].

The [averel]{.smallcaps} trial is designed to assess the efficacy and safety of first-line trastuzumab and docetaxel with or without bevacizumab in patients with [her]{.smallcaps}2-positive locally recurrent or metastatic breast cancer who have not received prior chemotherapy or radiotherapy for their metastatic disease. Patients will be stratified by prior adjuvant and neoadjuvant taxane chemotherapy and prior adjuvant trastuzumab therapy. Patients will be stratified by prior adjuvant or neoadjuvant taxane chemotherapy and prior adjuvant trastuzumab therapy. Patients must have completed adjuvant trastuzumab therapy 6 months or more before enrolment. The primary endpoint is progression-free survival; secondary endpoints are overall survival, overall response, duration of response, time to treatment failure, quality of life, and safety. The target sample size is 410 [@b49-co16-4-25].

The [ma]{.smallcaps}.31 ([complete]{.smallcaps}) trial being undertaken by the National Cancer Institute of Canada Clinical Trials Group is an international phase [iii]{.smallcaps} trial examining the efficacy and safety of first-line taxane-based chemotherapy combined with lapatinib (or trastuzumab) in patients with [her]{.smallcaps}2-positive metastatic disease. Patients are required to have had at least a 12-month interval from prior chemotherapy or [her]{.smallcaps}2-targeted therapy in the adjuvant or neoadjuvant setting. The primary endpoint is progression-free survival; secondary endpoints include overall survival, incidence rates of and time to central nervous system metastases at the time of progression, overall response rate, clinical benefit response rate, adverse event profile, quality of life, clinical outcomes using biomarkers, and health economics (including healthcare utilization and health utilities). The target sample size is 600 [@b50-co16-4-25].

3.4 Other Targeted Therapies
----------------------------

A variety of other novel targeted therapies are currently under investigation in women with [her]{.smallcaps}2-overexpressing [mbc]{.smallcaps} who may have received adjuvant trastuzumab-based therapy (that is, those who present with *de novo* metastatic disease) or for women who have progressed while receiving trastuzumab-based therapy for metastatic disease (second- or subsequent-line setting). In a phase [ii]{.smallcaps} trial, trastuzumab-[mcc]{.smallcaps}-[dm]{.smallcaps}1, a toxin-conjugated version of trastuzumab [@b51-co16-4-25], appears to offer improved efficacy and reduced toxicity over unconjugated trastuzumab in heavily pre-treated patients [@b52-co16-4-25]. An ongoing phase [iii]{.smallcaps} trial is currently evaluating trastuzumab- [mcc]{.smallcaps}-[dm]{.smallcaps}1 in comparison with the combination of capecitabine and lapatinib in patients with [her]{.smallcaps}2-positive locally advanced or metastatic breast cancer who have received prior trastuzumab-based therapy [@b53-co16-4-25].

The mammalian target of rapamycin, m[tor]{.smallcaps}, is a central regulator of G1 cell-cycle protein synthesis that precedes commitment to normal cellular replication. Inhibition of m[tor]{.smallcaps} has been shown to have antiproliferative activity in breast cancer by deregulation of the [pi]{.smallcaps}3[k]{.smallcaps}/Akt pathway [@b54-co16-4-25]--[@b56-co16-4-25]. One m[tor]{.smallcaps} inhibitor, deforolimus, is now being tested in combination with trastuzumab in a single-arm phase [ii]{.smallcaps} trial involving [her]{.smallcaps}2-positive trastuzumab-refractory [mbc]{.smallcaps} patients. For eligible patients, at least 4 weeks must have elapsed since earlier investigational therapy, chemotherapy, or radiotherapy [@b57-co16-4-25]. The [trio]{.smallcaps}-018 international phase [iii]{.smallcaps} study is evaluating the addition of everolimus (or placebo) to standard trastuzumab and weekly paclitaxel in the treatment of [her]{.smallcaps}2-positive advanced breast cancer [@b58-co16-4-25].

Histone deacetylase is another anticancer target that controls gene expression through transcription regulation [@b59-co16-4-25],[@b60-co16-4-25]. Panobinostat, an inhibitor of histone deacetylase [@b61-co16-4-25], is being studied in a single-arm phase [iib]{.smallcaps}/[iia]{.smallcaps} trial in combination with trastuzumab for [her]{.smallcaps}2-positive [mbc]{.smallcaps} patients who have progressed during or after trastuzumab treatment [@b62-co16-4-25]. Panobinostat is also being studied as monotherapy in the [trio]{.smallcaps}-016 study [@b63-co16-4-25].

Heat shock protein 90 (Hsp90) is a chaperone protein that enables cancer cell survival [@b64-co16-4-25]. The Hsp90 inhibitor IPI-504 is being investigated in a single-arm phase [ii]{.smallcaps} trial in combination with trastuzumab for patients with pretreated, locally advanced, or metastatic [her]{.smallcaps}2-positive breast cancer. Patients must have received at least two earlier regimens, with trastuzumab being a component in at least one (not including adjuvant regimens, unless progression on adjuvant treatment occurred) [@b65-co16-4-25].

The selective angiopoietin 1 and 2--neutralizing "peptibody" AMG 386 inhibits angiogenesis by preventing interaction of angiopoietins with Tie2 receptors [@b66-co16-4-25]. This agent is currently being studied in a phase [i]{.smallcaps} setting combining escalating doses of AMG 386 with paclitaxel and trastuzumab, and escalating doses of AMG 386 with capecitabine and lapatinib [@b67-co16-4-25].

4. DISCUSSION
=============

4.1 Treatment Beyond Progression
--------------------------------

Although retrospective case--cohort and prospective phase [ii]{.smallcaps} clinical trials (Level 3 evidence) have demonstrated safety and suggested possible clinical benefit from the continuation of trastuzumab beyond progression after first-line therapy in women with [her]{.smallcaps}2-positive [mbc]{.smallcaps}, it has been impossible to support the use of this strategy without higher quality (Level 1) evidence. The uncertainty of this therapeutic approach has been compounded by a lack of understanding of the mechanism of resistance to targeted therapies in [her]{.smallcaps}2-positive [mbc]{.smallcaps}. At the present time, a good definition of resistance from a mechanistic point of view is not available, leaving practitioners to rely on a clinical definition based on disease progression in relation to the targeted therapy. This area remains one of active, ongoing research.

The prospective randomized controlled trial conducted by the German Breast Group ([gbg]{.smallcaps} 26) demonstrated the clinical benefit of continuing trastuzumab with another chemotherapy partner (time to progression: 8.2 months vs. 5.6 months) [@b39-co16-4-25]. The absence of an overall survival advantage should not be a deterrent to the use of trastuzumab beyond first-line progression, because time to progression is an endpoint worthy of consideration. In addition, given that [gbg]{.smallcaps} 26 was prematurely stopped and that the targeted sample size was not reached, it is possible that the study was underpowered to detect a survival difference.

Two randomized phase [iii]{.smallcaps} trials have examined the role of combining (lapatinib--trastuzumab) or switching (trastuzumab to lapatinib plus capecitabine) targeted therapies in women with [her]{.smallcaps}2-positive [mbc]{.smallcaps}. Although these two studies do not directly address the question of continuing trastuzumab beyond progression (no arm without trastuzumab), the results support the contention that, in this population, continuing an anti-[her]{.smallcaps}2 targeted therapy may be reasonable.

### Panel Suggestion

It is highly unlikely that additional studies examining the specific role of trastuzumab combined with "second-line" chemotherapy will be forthcoming for women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} who have progressed on trastuzumab. The available evidence, including data from prospective randomized controlled trials, seems to support the continuation of [her]{.smallcaps}2-targeted therapy with trastuzumab or with lapatinib in combination with capecitabine. Despite these panel suggestions, the modest clinical benefits observed with this approach should encourage further research and participation in clinical trials for this patient population.

4.2 Re-treatment
----------------

No randomized clinical data support the use of trastuzumab or other anti-[her]{.smallcaps}2 therapies in women with [her]{.smallcaps}2-positive [mbc]{.smallcaps} who have received trastuzumab in the adjuvant setting. Several clinical trials are currently addressing this important clinical issue.

### Panel Suggestion

In the absence of data, and given the benefits seen in [mbc]{.smallcaps} patients who continue trastuzumab beyond progression, it would seem reasonable to consider re-treatment for patients exposed to adjuvant trastuzumab who have relapsed 6 months or more after adjuvant therapy. Participation in clinical trials for this patient population is encouraged.

5. CONCLUSIONS
==============

The authors of this manuscript developed treatment suggestions based on a review of the literature regarding treatment options for women with [her]{.smallcaps}2-positive [mbc]{.smallcaps}. The role of targeted therapies in this patient population will continue to evolve with the completion and publication of ongoing clinical trials.

5.1 Date of Author Suggestions
------------------------------

The panel suggestions were completed in March 2009.

Migliaccio I, Gutierrez MC, Wu MF, *et al.* PI3 kinase activation and response to trastuzumab or lapatinib in [her]{.smallcaps}-2 overexpressing locally advanced breast cancer ([labc]{.smallcaps}). Presented at the 31st Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 10--14, 2008.

###### 

Efficacy results from pivotal first-line metastatic breast cancer

  Clinical endpoint                   Trial arms Slamon *et al*., 2001[@b18-co16-4-25] (*n*=469)   Trial arms Marty et al., 2005 and 2006[@b19-co16-4-25],[@b20-co16-4-25] (*n*=186)          
  ----------------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------- ------ ------
  Median [orr]{.smallcaps} (%)        50                                                           32                                                                                  61     34
                                      *p\<*0.001                                                   *p=*0.0002                                                                                 
  Median [dr]{.smallcaps} (months)    9.1                                                          6.1                                                                                 11.7   5.7
                                      *p\<*0.001                                                   *p=*0.009                                                                                  
  Median [ttp]{.smallcaps} (months)   4.7                                                          4.6                                                                                 11.7   6.1
                                      *p\<*0.001                                                   *p=*0.0001                                                                                 
  Median [os]{.smallcaps} (months)    25.1                                                         20.3                                                                                31.2   22.7
                                      *p=*0.046                                                    *p=*0.0325[a](#tfn1-co16-4-25){ref-type="table-fn"}                                        

Trial survival results were updated at the 2006 San Antonio Breast Cancer Symposium. The superior survival benefit for trastuzumab docetaxel over docetaxel alone was maintained (31.2 months vs. 22.7 months); however, the survival difference was no longer significant (*p* = 0.0876), perhaps because most of the patients randomized to docetaxel alone (57%) subsequently crossed over to receive trastuzumab.

[orr]{.smallcaps} = objective response rate; [dr]{.smallcaps} = duration of response; [ttp]{.smallcaps} = time to progression; [os]{.smallcaps} = overall survival.

###### 

Response rates of trastuzumab in combination with chemotherapy in women with metastatic breast cancer progressing on trastuzumab: retrospective and case--cohort studies

  Reference                                     Patients[a](#tfn3-co16-4-25){ref-type="table-fn"} (*n*)   Therapy line                                                                                                                                                                                                               
  --------------------------------------------- --------------------------------------------------------- ------------------------------------------------------------------------------------------------------ ----- ------ -------------------------------------------- ------ ----- -------------------------------------------- ------------------
  Tokajuk *et al.,* 2006[@b21-co16-4-25]        14                                                        50                                                                                                     5.1   ---    ---                                          ---    ---   ---                                          ---
                                                                                                          (docetaxel, vinorelbine, cisplatin, capecitabine, etoposide, gemcitabine, and trastuzumab)                                                                                                                                 
  Stemmler *et al.,* 2005[@b22-co16-4-25]       23                                                        39.1                                                                                                   ---   ---    ---                                          ---    ---   ---                                          ---
                                                                                                          (taxane, vinorelbine, or other chemotherapy, and trastuzumab)                                                                                                                                                              
  Gelmon *et al.,* 2004[@b23-co16-4-25]         65                                                        32                                                                                                     ---   ---    ---                                          ---    ---   ---                                          ---
                                                                                                          (taxane, or vinorelbine and trastuzumab, or trastuzumab alone)                                                                                                                                                             
  García-Saénz *et al.,* 2006[@b24-co16-4-25]   47 (2nd line)                                             29.8                                                                                                   4     38.1   4                                            20     4     0[b](#tfn4-co16-4-25){ref-type="table-fn"}   [nr]{.smallcaps}
                                                21 (3rd line)                                                                                                                                                                                                                                                                        
                                                10 (4th line)                                                                                                                                                                                                                                                                        
                                                                                                          (chemotherapy and trastuzumab)                                                                                                                                                                                             
  Metro *et al.,* 2007[@b25-co16-4-25]          37 (2nd line)                                             29                                                                                                     6.7   0      4                                            0      4.5   ---                                          ---
                                                16 (3rd line)                                                                                                                                                                                                                                                                        
                                                9 (4th line)                                                                                                                                                                                                                                                                         
                                                                                                          (chemotherapy and trastuzumab)                                                                                                                                                                                             
  Fountzilas *et al.,* 2003[@b26-co16-4-25]     80 (2nd line)                                             23.8                                                                                                   5.2   14.3   3.5                                          19.2   4.9   8.3                                          3.9
                                                49 (3rd line)                                                                                                                                                                                                                                                                        
                                                26 (4th line)                                                                                                                                                                                                                                                                        
                                                12 (5th line)                                                                                                                                                                                                                                                                        
                                                                                                          (vinorelbine or gemcitabine and trastuzumab)                                                                                                                                                                               
  Adamo *et al.,* 2007[@b27-co16-4-25]          26 (2nd line)                                             23                                                                                                     9     22     9[c](#tfn5-co16-4-25){ref-type="table-fn"}   ---    ---   ---                                          ---
                                                9 (3rd line)                                                                                                                                                                                                                                                                         
                                                                                                          (vinorelbine, taxane, pegylated liposomal doxorubicin, or gemcitabine and trastuzumab)                                                                                                                                     
  Montemurro *et al.,* 2006[@b28-co16-4-25]     40                                                        18                                                                                                     ---   ---    ---                                          ---    ---   ---                                          ---
                                                                                                          (vinorelbine, taxanes, liposomal doxorubicin, capecitabine, letrozole, or tamoxifen and trastuzumab)                                                                                                                       
  Fabi *et al.,* 2008[@b29-co16-4-25]           59                                                        27                                                                                                     6.7   ---    ---                                          ---    ---   ---                                          ---
                                                                                                          (chemotherapy and trastuzumab)                                                                                                                                                                                             

Those who received trastuzumab treatment beyond progression (in the second line, unless otherwise stated).

Stable disease 60%.

Reported for third-line treatment and beyond.

[orr]{.smallcaps} = overall response rate; [ttp]{.smallcaps} = time to progression; [nr]{.smallcaps} = not reported.

###### 

Response rates for trastuzumab in combination with chemotherapy in women with metastatic breast cancer progressing on trastuzumab, prospective phase [ii]{.smallcaps} trials

  Reference                                   Patients[a](#tfn7-co16-4-25){ref-type="table-fn"} (*n*)   Therapy line                                                                                            
  ------------------------------------------- --------------------------------------------------------- --------------------------------------------------- -------------------------------------------- ------ -----
  Tripathy *et al.,* 2004[@b30-co16-4-25]     93                                                        11                                                  ---                                          ---    ---
                                                                                                        (chemotherapy and trastuzumab)                                                                          
  Morabito *et al.,* 2006[@b31-co16-4-25]     7                                                         29                                                  ---                                          ---    ---
                                                                                                        (vinorelbine, gemcitabine, and trastuzumab)                                                             
  Orlando *et al.,* 2006[@b32-co16-4-25]      11                                                        18                                                  6                                            ---    ---
                                                                                                        (cyclophosphamide, methotrexate, and trastuzumab)                                                       
  Del Bianco *et al.,* 2006[@b33-co16-4-25]   8 (2nd line)                                              50                                                  8                                            62.5   9
                                              8 (3rd line)                                                                                                                                                      
                                                                                                        (chemotherapy and trastuzumab)                                                                          
  Bartsch *et al.,* 2007[@b34-co16-4-25]      40                                                        20[b](#tfn8-co16-4-25){ref-type="table-fn"}         8[b](#tfn8-co16-4-25){ref-type="table-fn"}   ---    ---
                                                                                                        (capecitabine and trastuzumab)                                                                          
  Bachelot *et al.,* 2007[@b35-co16-4-25]     17                                                        29                                                  ---                                          ---    ---
                                                                                                        (vinorelbine and trastuzumab)                                                                           
  Modi *et al.,* 2007[@b36-co16-4-25]         20                                                        25                                                  ---                                          ---    ---
                                                                                                        (tanespimycin and trastuzumab)                                                                          

Those who received trastuzumab treatment beyond progression (in the second line, unless otherwise stated).

Reported for second-line treatment and beyond.

[orr]{.smallcaps} = overall response rate; [ttp]{.smallcaps} = time to progression.

###### 

Summary of efficacy data from French Hermine cohort study[@b38-co16-4-25]

                                     Efficacy endpoint                Therapy line                                                          
  ---------------------------------- -------------------------------- ------------------------------------------------------- ------ ------ ------
  Median [os]{.smallcaps} (months)   From initiation of trastuzumab   Not reached[b](#tfn11-co16-4-25){ref-type="table-fn"}   16.8   27.2   15.6
                                     From date of progression         21.3                                                    4.6    15.5   11
  [os]{.smallcaps} at 2 years (%)    From initiation of trastuzumab   73.7                                                    24.7   55.7   41.8

Follow-up data are available for only 177 of the 221 patients who received first-line trastuzumab-based

After a median follow-up of 27.8 months.

[os]{.smallcaps} = overall survival.

###### 

Summary of efficacy data from the German Breast Group 26 trial

  Clinical endpoint            Trial arms von Minckwitz *et al*., 2009[@b39-co16-4-25] (*n*=152)   
  ---------------------------- ------------------------------------------------------------------- ------
  [ttp]{.smallcaps} (months)   8.2                                                                 5.6
                               *p=*0.0338                                                          
  [orr]{.smallcaps} (%)        48.1                                                                27.0
                               *p=*0.0115                                                          
  [cbr]{.smallcaps} (%)        75.3                                                                54.0
                               *p=*0.0068                                                          
  [os]{.smallcaps} (months)    25.5                                                                20.4
                               *p=*0.257                                                           

[ttp]{.smallcaps} = time to progression; [orr]{.smallcaps} = overall response rate; [cbr]{.smallcaps} = clinical benefit rate; [os]{.smallcaps} = overall survival.

###### 

Summary of efficacy data from trials by Geyer *et al.*

  Clinical endpoint           Trial arms Geyer *et al*., 2006 and 2007[@b40-co16-4-25],[@b41-co16-4-25] (*n*=324)   
  --------------------------- ------------------------------------------------------------------------------------- ----------------------------------------------
  [ttp]{.smallcaps} (weeks)   27[a](#tfn14-co16-4-25){ref-type="table-fn"}                                          19[a](#tfn14-co16-4-25){ref-type="table-fn"}
                              *p=*0.00013[a](#tfn14-co16-4-25){ref-type="table-fn"}                                 
  [pfs]{.smallcaps} (%)       8.4                                                                                   4.1
                              *p\<*0.001                                                                            
  [orr]{.smallcaps} (%)       24[a](#tfn14-co16-4-25){ref-type="table-fn"}                                          14[a](#tfn14-co16-4-25){ref-type="table-fn"}
                              *p=*0.017[a](#tfn14-co16-4-25){ref-type="table-fn"}                                   
  [cbr]{.smallcaps} (%)       44                                                                                    29
                              [nr]{.smallcaps}                                                                      
  [os]{.smallcaps} (months)   [nr]{.smallcaps}                                                                      [nr]{.smallcaps}
                              *p=*0.177[a](#tfn14-co16-4-25){ref-type="table-fn"}                                   

Based on updated data presented in 2007.

[ttp]{.smallcaps} = time to progression; [pfs]{.smallcaps} = progression-free survival; [orr]{.smallcaps} = objective response rate; [cbr]{.smallcaps} = clinical benefit rate; [nr]{.smallcaps} = not reported; [os]{.smallcaps} = overall survival.
